< Back to previous page

Patent

Treatment of central nervous tumours

The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).
Patent Publication Number: EP3380087
Year filing: 2022
Year approval: 2022
Year publication: 2022
Status: Assigned
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven